abt-20260331

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES


An Illinois Corporation			I.R.S. Employer Identification No.
			36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange NYSE Texas

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer x			Accelerated Filer o

Non-Accelerated Filer o			Smaller reporting company o

			Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of March 31, 2026, Abbott Laboratories had 1,741,812,429 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents


Part I - Financial Information
			Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings			3
Condensed Consolidated Statement of Comprehensive Income			4
Condensed Consolidated Balance Sheet			5
Condensed Consolidated Statement of Shareholders’ Investment			6
Condensed Consolidated Statement of Cash Flows			7
Notes to the Condensed Consolidated Financial Statements			8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			22

Item 4. Controls and Procedures			28

Part II - Other Information			28

Item 1. Legal Proceedings			28

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			29

Item 6. Exhibits			30

Signature			33

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)


	Three Months Ended
	March 31
	2026		2025
Net sales	$	11,164	$	10,358

Cost of products sold, excluding amortization of intangible assets	4,890		4,468
Amortization of intangible assets	422		420
Research and development	767		716
Selling, general, and administrative	3,740		3,061
Total operating cost and expenses	9,819		8,665

Operating earnings	1,345		1,693

Interest expense	174		131
Interest (income)	(106)		(82)
Net foreign exchange (gain) loss	(13)		(7)
Other (income) expense, net	(159)		(127)
Earnings before taxes	1,449		1,778
Taxes on earnings	372		453
Net Earnings	$	1,077	$	1,325

Basic Earnings Per Common Share	$	0.62	$	0.76

Diluted Earnings Per Common Share	$	0.61	$	0.76

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,742,480		1,739,206
Dilutive Common Stock Options	4,593		8,014
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,747,073		1,747,220

Outstanding Common Stock Options Having No Dilutive Effect	9,900		1,431

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)


	Three Months Ended
	March 31
	2026		2025
Net Earnings	$	1,077	$	1,325
Foreign currency translation gain (loss) adjustments, net of taxes of $(11) in 2026 and $32 in 2025	(400)		550
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 in 2026 and $— in 2025	(13)		30
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $32 in 2026 and $(40) in 2025	102		(91)
Other comprehensive income (loss)	(311)		489
Comprehensive Income	$	766	$	1,814


	March 31, 2026		December 31, 2025
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(6,331)	$	(5,931)
Net actuarial (losses) and prior service (costs) and credits	(14)		(1)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges	33		(69)
Accumulated other comprehensive income (loss)	$	(6,312)	$	(6,001)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)


	March 31, 2026		December 31, 2025
Assets
Current Assets:
Cash and cash equivalents	$	6,803	$	8,522
Short-term investments	492		417
Trade receivables, less allowances of $494 in 2026 and $490 in 2025	8,210		7,929
Inventories:
Finished products	4,274		3,976
Work in process	994		904
Materials	1,721		1,608
Total inventories	6,989		6,488
Prepaid expenses and other receivables	3,014		2,640
Total Current Assets	25,508		25,996
Investments	1,090		918
Property and equipment, at cost	25,737		25,222
Less: accumulated depreciation and amortization	13,360		13,406
Net property and equipment	12,377		11,816
Intangible assets, net of amortization	17,875		5,526
Goodwill	35,221		24,035
Deferred income taxes and other assets	18,358		18,422
	$	110,429	$	86,713
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable	$	4,679	$	4,240
Salaries, wages, and commissions	1,212		1,745
Other accrued liabilities	6,379		5,812
Dividends payable	1,100		1,097
Income taxes payable	598		569
Current portion of long-term debt	4,409		3,033
Total Current Liabilities	18,377		16,496
Long-term debt	29,638		9,896
Post-employment obligations, deferred income taxes, and other long-term liabilities	9,713		7,550
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2026: 1,998,233,756; 2025: 1,996,795,525	25,352		25,527
Common shares held in treasury, at cost — Shares: 2026: 256,420,602; 2025: 260,196,074	(16,935)		(17,177)
Earnings employed in the business	49,956		49,781
Accumulated other comprehensive income (loss)	(6,312)		(6,001)
Total Abbott Shareholders’ Investment	52,061		52,130
Noncontrolling interests	640		641
Total Shareholders’ Investment	52,701		52,771
	$	110,429	$	86,713

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


	Three Months Ended March 31
	2026		2025
Common Shares:
Balance at January 1
Shares: 2026: 1,996,795,525; 2025: 1,991,472,630	$	25,527	$	25,153
Issued under incentive stock programs
Shares: 2026: 1,438,231; 2025: 4,385,976	59		239
Share-based compensation	330		303
Issuance of restr

SEC Form 10-Q filed by Abbott Laboratories